氯氮平联合利培酮治疗难治性精神分裂症的临床疗效

发布时间：2019-03-07 23:37

【摘要】：目的探讨氯氮平与利培酮联合治疗难治性精神分裂症(TRS)临床效果。方法 100例难治性精神分裂症患者按治疗方案不同随机分为观察组和对照组,各50例。对照组给予氯氮平治疗,观察组给予氯氮平联合利培酮治疗,连续治疗12周,对比两组临床治疗效果、不良反应发生率,用阳性与阴性症状(PANSS)量表评估治疗前、治疗2、4、8、12周后症状改善情况,用简明健康调查量表(SF-36)评估治疗前、治疗12周后生活质量变化情况。结果观察组总有效率高于对照组(P0.05);治疗2、4、8、12周后PANSS评分低于对照组(P0.05);治疗12周后SF-36评分高于对照组(P0.05)。结论氯氮平联合利培酮治疗难治性精神分裂症疗效显著,可改善其阳性及阴性症状。
[Abstract]:Objective to investigate the clinical effect of clozapine combined with risperidone in the treatment of refractory schizophrenia with (TRS). Methods 100 patients with refractory schizophrenia were randomly divided into observation group (n = 50) and control group (n = 50). The patients in the control group were treated with clozapine and risperidone for 12 weeks. The clinical effects and the incidence of adverse reactions were compared between the two groups. The (PANSS) scale for positive and negative symptoms was used to evaluate the treatment before treatment. The symptoms were improved after 8 and 12 weeks, and the quality of life was evaluated before and 12 weeks after treatment with the Concise Health Survey scale (SF-36). Results the total effective rate of the observation group was higher than that of the control group (P0.05), the PANSS score was lower than that of the control group at 2,4,8,12 weeks after treatment (P0.05), and the SF-36 score was higher than that of the control group after 12 weeks of treatment (P0.05). Conclusion clozapine combined with risperidone is effective in the treatment of refractory schizophrenia and can improve its positive and negative symptoms.
【作者单位】： 河北省第六人民医院;
【基金】：河北省卫生厅科研基金,编号:20120254
【分类号】：R749.3
，

本文编号：2436563